DOCSLIB.ORG

Quantibody Sensitivity

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Quantibody Sensitivity Human Cytokines Sensitivity (pg/ml) 4-1BB (CD137) 8 4-1BB (CD137) (8pg/ml) 6Ckine 40 6Ckine (40pg/ml) ACE-2 200 ACE-2 (200pg/ml) Activin A 80 Activin A (80pg/ml) Adiponectin 16 Adiponectin (16pg/ml) Adipsin 20 Adipsin (20pg/ml) AgRP(ART) 10 AgRP(ART) (10pg/ml) ALCAM 8 ALCAM (8pg/ml) Angiogenin 4 Angiogenin (4pg/ml) Angiopoietin-1 100 Angiopoietin-1 (100pg/ml) Angiopoietin-2 8 Angiopoietin-2 (8pg/ml) Angiostatin 2000 Angiostatin (2000pg/ml) ANGPTL4 200 ANGPTL4 (200pg/ml) AR (amphiregulin) 8 AR (amphiregulin) (8pg/ml) Axl 8 Axl (8pg/ml) B2M 20 B2M (20pg/ml) B7-1(CD80) 16 B7-1(CD80) (16pg/ml) BCAM 20 BCAM (20pg/ml) BDNF 4 BDNF (4pg/ml) bFGF 8 bFGF (8pg/ml) BLC 4 BLC (4pg/ml) BMP-5 200 BMP-5 (200pg/ml) BMP-7 80 BMP-7 (80pg/ml) b-NGF 16 b-NGF (16pg/ml) BTC 40 BTC (40pg/ml) Cardiotrophin-1 200 Cardiotrophin-1 (200pg/ml) Cathepsin S 20 Cathepsin S (20pg/ml) CCL28/VIC 40 CCL28/VIC (40pg/ml) CD14 20 CD14 (20pg/ml) CD40L 20 CD40L (20pg/ml) CNTF 200 CNTF (200pg/ml) CRP 2 CRP (2pg/ml) CTACK/CCL27 16 CTACK/CCL27 (16pg/ml) CXCL16 4 CXCL16 (4pg/ml) DAN 20 DAN (20pg/ml) Dkk-1 20 Dkk-1 (20pg/ml) DR6 8 DR6 (8pg/ml) Dtk 40 Dtk (40pg/ml) E-Cadherin 20 E-Cadherin (20pg/ml) EGF 0.2 EGF (0.2pg/ml) EGF R 20 EGF R (20pg/ml) ENA-78 20 ENA-78 (20pg/ml) Endoglin(CD105) 8 Endoglin(CD105) (8pg/ml) Eotaxin 8 Eotaxin (8pg/ml) Eotaxin-2 2 Eotaxin-2 (2pg/ml) Eotaxin-3 200 Eotaxin-3 (200pg/ml) EPO R 2 EPO R (2pg/ml) ErbB3 20 ErbB3 (20pg/ml) E-Selectin 80 E-Selectin (80pg/ml) Fas Ligand 2 Fas Ligand (2pg/ml) Fas/TNFRSF6 4 Fas/TNFRSF6 (4pg/ml) Fcr RII 20 Fcr RII (20pg/ml) FGF-4 200 FGF-4 (200pg/ml) FGF-6 200 FGF-6 (200pg/ml) FGF-7 40 FGF-7 (40pg/ml) Fit-3 Ligand 4 Fit-3 Ligand (4pg/ml) GCP-2 20 GCP-2 (20pg/ml) GCSF 20 GCSF (20pg/ml) GDNF 2 GDNF (2pg/ml) GITR/TNFRF18 16 GITR/TNFRF18 (16pg/ml) GM-CSF 2 GM-CSF (2pg/ml) GRO 2 GRO (2pg/ml) GROa 60 GROa (60pg/ml) Growth Hormone 20 Growth Hormone (20pg/ml) HB-EGF 8 HB-EGF (8pg/ml) HCC-1 2 HCC-1 (2pg/ml) HCC-4/CCL16 4 HCC-4/CCL16 (4pg/ml) HGF 8 HGF (8pg/ml) HVEM 2 HVEM (2pg/ml) I-309 8 I-309 (8pg/ml) ICAM-1 80 ICAM-1 (80pg/ml) ICAM-2 40 ICAM-2 (40pg/ml) ICAM-3 20 ICAM-3 (20pg/ml) IFNg 4 IFNg (4pg/ml) IGFBP-1 16 IGFBP-1 (16pg/ml) IGFBP-2 40 IGFBP-2 (40pg/ml) IGFBP-3 1600 IGFBP-3 (1600pg/ml) IGFBP-4 200 IGFBP-4 (200pg/ml) IGFBP-6 40 IGFBP-6 (40pg/ml) IGF-I 40 IGF-I (40pg/ml) IGF-I SR 160 IGF-I SR (160pg/ml) IL-1 R4/ST2 8 IL-1 R4/ST2 (8pg/ml) IL-1 sRI 8 IL-1 sRI (8pg/ml) IL-1 sRII 40 IL-1 sRII (40pg/ml) IL-10 2 IL-10 (2pg/ml) IL-10 R beta 8 IL-10 R beta (8pg/ml) IL-11 40 IL-11 (40pg/ml) IL-12 p40 8 IL-12 p40 (8pg/ml) IL-12 p70 1 IL-12 p70 (1pg/ml) IL-13 2 IL-13 (2pg/ml) IL-13Ra 80 IL-13Ra (80pg/ml) IL-15 8 IL-15 (8pg/ml) IL-16 8 IL-16 (8pg/ml) IL-17 8 IL-17 (8pg/ml) IL-17B 20 IL-17B (20pg/ml) IL-18 8 IL-18 (8pg/ml) IL-18 BPa 20 IL-18 BPa (20pg/ml) IL-18 R beta 8 IL-18 R beta (8pg/ml) IL-1a 4 IL-1a (4pg/ml) IL-1b 2 IL-1b (2pg/ml) IL-1ra 40 IL-1ra (40pg/ml) IL-2 2 IL-2 (2pg/ml) IL-2 R gamma 20 IL-2 R gamma (20pg/ml) IL-2 sRa 4 IL-2 sRa (4pg/ml) IL-21 R 40 IL-21 R (40pg/ml) IL-28A 20 IL-28A (20pg/ml) IL-3 20 IL-3 (20pg/ml) IL-4 4 IL-4 (4pg/ml) IL-5 4 IL-5 (4pg/ml) IL-6 4 IL-6 (4pg/ml) IL-6 sR 4 IL-6 sR (4pg/ml) IL-7 8 IL-7 (8pg/ml) IL-8 1 IL-8 (1pg/ml) IL-9 80 IL-9 (80pg/ml) Insulin 200 Insulin (200pg/ml) IP-10 4 IP-10 (4pg/ml) I-TAC/CXCL11 4 I-TAC/CXCL11 (4pg/ml) LAP(TGF-b1) 16 LAP(TGF-b1) (16pg/ml) Leptin 20 Leptin (20pg/ml) Leptin R 2000 Leptin R (2000pg/ml) LIF 8 LIF (8pg/ml) LIGHT 8 LIGHT (8pg/ml) L-Selectin 80 L-Selectin (80pg/ml) Lymphotactin 160 Lymphotactin (160pg/ml) MCP-1 4 MCP-1 (4pg/ml) MCP-2 200 MCP-2 (200pg/ml) MCP-3 40 MCP-3 (40pg/ml) MCP-4 8 MCP-4 (8pg/ml) M-CSF 8 M-CSF (8pg/ml) M-CSF R 80 M-CSF R (80pg/ml) MICA 8 MICA (8pg/ml) MICB 20 MICB (20pg/ml) MIF 800 MIF (800pg/ml) MIG 8 MIG (8pg/ml) MIP-1a 8 MIP-1a (8pg/ml) MIP-1b 2 MIP-1b (2pg/ml) MIP-1d 12 MIP-1d (12pg/ml) MIP-3a 2 MIP-3a (2pg/ml) MIP-3b 4 MIP-3b (4pg/ml) MMP-1 100 MMP-1 (100pg/ml) MMP-10 10 MMP-10 (10pg/ml) MMP-13 40 MMP-13 (40pg/ml) MMP-2 100 MMP-2 (100pg/ml) MMP-3 60 MMP-3 (60pg/ml) MMP-8 40 MMP-8 (40pg/ml) MMP-9 40 MMP-9 (40pg/ml) MPIF-1 200 MPIF-1 (200pg/ml) MSP a 10 MSP a (10pg/ml) NAP-2 40 NAP-2 (40pg/ml) NGF R 4 NGF R (4pg/ml) NT-3 20 NT-3 (20pg/ml) NT-4 8 NT-4 (8pg/ml) OSM 8 OSM (8pg/ml) Ost 8 Ost (8pg/ml) PAI-1 80 PAI-1 (80pg/ml) PARC 2 PARC (2pg/ml) PDGF R beta 20 PDGF R beta (20pg/ml) PDGF-AA 40 PDGF-AA (40pg/ml) PDGF-AB 40 PDGF-AB (40pg/ml) PDGF-BB 2 PDGF-BB (2pg/ml) PECAM-1 20 PECAM-1 (20pg/ml) PF4 2 PF4 (2pg/ml) PlGF 8 PlGF (8pg/ml) Prolactin 600 Prolactin (600pg/ml) P-Selectin 10 P-Selectin (10pg/ml) RAGE 40 RAGE (40pg/ml) RANK 200 RANK (200pg/ml) RANKL (TRANCE) 200 RANKL (TRANCE) (200pg/ml) RANTES 4 RANTES (4pg/ml) Resistin 20 Resistin (20pg/ml) SAA 40 SAA (40pg/ml) SCF 8 SCF (8pg/ml) SCF R 40 SCF R (40pg/ml) SDF-1 200 SDF-1 (200pg/ml) SDF-1b 80 SDF-1b (80pg/ml) sgp130 10 sgp130 (10pg/ml) Siglec-5 16 Siglec-5 (16pg/ml) sTNF RII/TNFRS1B 2 sTNF RII/TNFRS1B (2pg/ml) sTNT RI/TNFRS1A 2 sTNT RI/TNFRS1A (2pg/ml) TARC 20 TARC (20pg/ml) TECK/CCL25 160 TECK/CCL25 (160pg/ml) TGF-a 4 TGF-a (4pg/ml) TGF-b1 20 TGF-b1 (20pg/ml) TGF-b2 40 TGF-b2 (40pg/ml) TGF-b3 20 TGF-b3 (20pg/ml) Tie-1 1000 Tie-1 (1000pg/ml) Tie-2 40 Tie-2 (40pg/ml) TIMP-1 40 TIMP-1 (40pg/ml) TIMP-2 40 TIMP-2 (40pg/ml) TIMP-4 100 TIMP-4 (100pg/ml) TNFa 4 TNFa (4pg/ml) TNFb 20 TNFb (20pg/ml) TPO 160 TPO (160pg/ml) TRAIL s R3/TNFRS10C 10 TRAIL s R3/TNFRS10C (10pg/ml) TRAIL s R4/TNFRS10D 40 TRAIL s R4/TNFRS10D (40pg/ml) TREM-1 20 TREM-1 (20pg/ml) u PAR 80 u PAR (80pg/ml) VCAM-1 200 VCAM-1 (200pg/ml) VEGF 8 VEGF (8pg/ml) VEGF R2 20 VEGF R2 (20pg/ml) VEGF R3 80 VEGF R3 (80pg/ml) VEGF-D 16 VEGF-D (16pg/ml) XEDAR 8 XEDAR (8pg/ml).
Load more

Recommended publications
  • Fog2 Is Critical for Cardiac Function and Maintenance of Coronary Vasculature in the Adult Mouse Heart
    Fog2 is critical for cardiac function and maintenance of coronary vasculature in the adult mouse heart Bin Zhou, … , Sergei G. Tevosian, William T. Pu J Clin Invest. 2009;119(6):1462-1476. https://doi.org/10.1172/JCI38723. Research Article Cardiology Aberrant transcriptional regulation contributes to the pathogenesis of both congenital and adult forms of heart disease. While the transcriptional regulator friend of Gata 2 (FOG2) is known to be essential for heart morphogenesis and coronary development, its tissue-specific function has not been previously investigated. Additionally, little is known about the role of FOG2 in the adult heart. Here we used spatiotemporally regulated inactivation of Fog2 to delineate its function in both the embryonic and adult mouse heart. Early cardiomyocyte-restricted loss of Fog2 recapitulated the cardiac and coronary defects of the Fog2 germline murine knockouts. Later cardiomyocyte-restricted loss ofF og2 (Fog2MC) did not result in defects in cardiac structure or coronary vessel formation. However, Fog2MC adult mice had severely depressed ventricular function and died at 8–14 weeks. Fog2MC adult hearts displayed a paucity of coronary vessels, associated with myocardial hypoxia, increased cardiomyocyte apoptosis, and cardiac fibrosis. Induced inactivation of Fog2 in the adult mouse heart resulted in similar phenotypes, as did ablation of the FOG2 interaction with the transcription factor GATA4. Loss of the FOG2 or FOG2-GATA4 interaction altered the expression of a panel of angiogenesis-related genes. Collectively, our data indicate that FOG2 regulates adult heart function and coronary angiogenesis. Find the latest version: https://jci.me/38723/pdf Research article Fog2 is critical for cardiac function and maintenance of coronary vasculature in the adult mouse heart Bin Zhou,1,2 Qing Ma,1 Sek Won Kong,1 Yongwu Hu,1,3 Patrick H.
    [Show full text]
  • Cytokine Nomenclature
    RayBiotech, Inc. The protein array pioneer company Cytokine Nomenclature Cytokine Name Official Full Name Genbank Related Names Symbol 4-1BB TNFRSF Tumor necrosis factor NP_001552 CD137, ILA, 4-1BB ligand receptor 9 receptor superfamily .2. member 9 6Ckine CCL21 6-Cysteine Chemokine NM_002989 Small-inducible cytokine A21, Beta chemokine exodus-2, Secondary lymphoid-tissue chemokine, SLC, SCYA21 ACE ACE Angiotensin-converting NP_000780 CD143, DCP, DCP1 enzyme .1. NP_690043 .1. ACE-2 ACE2 Angiotensin-converting NP_068576 ACE-related carboxypeptidase, enzyme 2 .1 Angiotensin-converting enzyme homolog ACTH ACTH Adrenocorticotropic NP_000930 POMC, Pro-opiomelanocortin, hormone .1. Corticotropin-lipotropin, NPP, NP_001030 Melanotropin gamma, Gamma- 333.1 MSH, Potential peptide, Corticotropin, Melanotropin alpha, Alpha-MSH, Corticotropin-like intermediary peptide, CLIP, Lipotropin beta, Beta-LPH, Lipotropin gamma, Gamma-LPH, Melanotropin beta, Beta-MSH, Beta-endorphin, Met-enkephalin ACTHR ACTHR Adrenocorticotropic NP_000520 Melanocortin receptor 2, MC2-R hormone receptor .1 Activin A INHBA Activin A NM_002192 Activin beta-A chain, Erythroid differentiation protein, EDF, INHBA Activin B INHBB Activin B NM_002193 Inhibin beta B chain, Activin beta-B chain Activin C INHBC Activin C NM005538 Inhibin, beta C Activin RIA ACVR1 Activin receptor type-1 NM_001105 Activin receptor type I, ACTR-I, Serine/threonine-protein kinase receptor R1, SKR1, Activin receptor-like kinase 2, ALK-2, TGF-B superfamily receptor type I, TSR-I, ACVRLK2 Activin RIB ACVR1B
    [Show full text]
  • GP130 Cytokines in Breast Cancer and Bone
    cancers Review GP130 Cytokines in Breast Cancer and Bone Tolu Omokehinde 1,2 and Rachelle W. Johnson 1,2,3,* 1 Program in Cancer Biology, Vanderbilt University, Nashville, TN 37232, USA; [email protected] 2 Vanderbilt Center for Bone Biology, Department of Medicine, Division of Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, TN 37232, USA 3 Department of Medicine, Division of Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, TN 37232, USA * Correspondence: [email protected]; Tel.: +1-615-875-8965 Received: 14 December 2019; Accepted: 29 January 2020; Published: 31 January 2020 Abstract: Breast cancer cells have a high predilection for skeletal homing, where they may either induce osteolytic bone destruction or enter a latency period in which they remain quiescent. Breast cancer cells produce and encounter autocrine and paracrine cytokine signals in the bone microenvironment, which can influence their behavior in multiple ways. For example, these signals can promote the survival and dormancy of bone-disseminated cancer cells or stimulate proliferation. The interleukin-6 (IL-6) cytokine family, defined by its use of the glycoprotein 130 (gp130) co-receptor, includes interleukin-11 (IL-11), leukemia inhibitory factor (LIF), oncostatin M (OSM), ciliary neurotrophic factor (CNTF), and cardiotrophin-1 (CT-1), among others. These cytokines are known to have overlapping pleiotropic functions in different cell types and are important for cross-talk between bone-resident cells. IL-6 cytokines have also been implicated in the progression and metastasis of breast, prostate, lung, and cervical cancer, highlighting the importance of these cytokines in the tumor–bone microenvironment. This review will describe the role of these cytokines in skeletal remodeling and cancer progression both within and outside of the bone microenvironment.
    [Show full text]
  • Association of Cardiotrophin-Like Cytokine Factor 1 Levels in Peripheral
    Chen et al. BMC Musculoskeletal Disorders (2021) 22:62 https://doi.org/10.1186/s12891-020-03924-9 RESEARCH ARTICLE Open Access Association of cardiotrophin-like cytokine factor 1 levels in peripheral blood mononuclear cells with bone mineral density and osteoporosis in postmenopausal women Xuan Chen1†, Jianyang Li2†, Yunjin Ye1, Jingwen Huang1, Lihua Xie1, Juan Chen1, Shengqiang Li1, Sainan Chen1 and Jirong Ge1* Abstract Background: Recent research has suggested that cardiotrophin-like cytokine factor 1 (CLCF1) may be an important regulator of bone homeostasis. Furthermore, a whole gene chip analysis suggested that the expression levels of CLCF1 in the peripheral blood mononuclear cells (PBMCs) were downregulated in postmenopausal women with osteoporosis. This study aimed to assess whether the expression levels of CLCF1 in PBMCs can reflect the severity of bone mass loss and the related fracture risk. Methods: In all, 360 postmenopausal women, aged 50 to 80 years, were included in the study. A survey to evaluate the participants’ health status, measurement of bone mineral density (BMD), routine blood test, and CLCF1 expression level test were performed. Results: Based on the participants’ bone health, 27 (7.5%), 165 (45.83%), and 168 (46.67%) participants were divided into the normal, osteopenia, and osteoporosis groups, respectively. CLCF1 protein levels in the normal and osteopenia groups were higher than those in the osteoporosis group. While the CLCF1 mRNA level was positively associated with the BMD of total femur (r =0.169,p = 0.011) and lumbar spine (r =0.176,p = 0.001), the protein level was positively associated with the BMD of the lumbar spine (r =0.261,p <0.001),femoralneck(r =0.236,p = 0.001), greater trochanter (r =0.228,p =0.001),andWard’striangle(r =0.149,p = 0.036).
    [Show full text]
  • Development and Validation of a Protein-Based Risk Score for Cardiovascular Outcomes Among Patients with Stable Coronary Heart Disease
    Supplementary Online Content Ganz P, Heidecker B, Hveem K, et al. Development and validation of a protein-based risk score for cardiovascular outcomes among patients with stable coronary heart disease. JAMA. doi: 10.1001/jama.2016.5951 eTable 1. List of 1130 Proteins Measured by Somalogic’s Modified Aptamer-Based Proteomic Assay eTable 2. Coefficients for Weibull Recalibration Model Applied to 9-Protein Model eFigure 1. Median Protein Levels in Derivation and Validation Cohort eTable 3. Coefficients for the Recalibration Model Applied to Refit Framingham eFigure 2. Calibration Plots for the Refit Framingham Model eTable 4. List of 200 Proteins Associated With the Risk of MI, Stroke, Heart Failure, and Death eFigure 3. Hazard Ratios of Lasso Selected Proteins for Primary End Point of MI, Stroke, Heart Failure, and Death eFigure 4. 9-Protein Prognostic Model Hazard Ratios Adjusted for Framingham Variables eFigure 5. 9-Protein Risk Scores by Event Type This supplementary material has been provided by the authors to give readers additional information about their work. Downloaded From: https://jamanetwork.com/ on 10/02/2021 Supplemental Material Table of Contents 1 Study Design and Data Processing ......................................................................................................... 3 2 Table of 1130 Proteins Measured .......................................................................................................... 4 3 Variable Selection and Statistical Modeling ........................................................................................
    [Show full text]
  • Novel Neurotrophin-1/B Cell-Stimulating Factor-3
    Proc. Natl. Acad. Sci. USA Vol. 96, pp. 11458–11463, September 1999 Immunology Novel neurotrophin-1͞B cell-stimulating factor-3: A cytokine of the IL-6 family GIORGIO SENALDI*, BRIAN C. VARNUM,ULLA SARMIENTO,CHARLIE STARNES,JACKSON LILE,SHEILA SCULLY, JANE GUO,GARY ELLIOTT,JENNIFER MCNINCH,CHRISTINE L. SHAKLEE,DANIEL FREEMAN,FRANK MANU, W. SCOTT SIMONET,THOMAS BOONE, AND MING-SHI CHANG Amgen Inc., Thousand Oaks, CA 91320 Edited by Charles A. Dinarello, University of Colorado Health Science Center, Denver, CO, and approved July 29, 1999 (received for review April 12, 1999) ABSTRACT We have identified a cytokine of the IL-6 potentiate the elevation of serum levels of corticosterone and family and named it novel neurotrophin-1͞B cell-stimulating IL-6 triggered by IL-1 (20). Furthermore, IL-6, IL-11, LIF, and factor-3 (NNT-1͞BSF-3). NNT-1͞BSF-3 cDNA was cloned CNTF cause body weight (BW) loss and͞or food intake from activated Jurkat human T cell lymphoma cells. Its reduction (21, 22), and IL-6, IL-11, LIF, and OM stimulate sequence predicts a 225-aa protein with a 27-aa signal peptide, hematopoiesis, especially platelet production (23–26). IL-6 has a molecular mass of 22 kDa in mature form, and the highest pronounced effects on adaptive immunity (27). Indeed, IL-6 homology to cardiotrophin-1 and ciliary neurotrophic factor. was originally described as a B cell differentiation or stimu- The gene for NNT-1͞BSF-3 is on chromosome 11q13. A lating factor (28, 29) and as a hybridoma growth factor (30), murine equivalent to NNT-1͞BSF-3 also was identified, which promoting the development of B cells and Ab production (27).
    [Show full text]
  • The Role of Inflammation in Heart Failure: New Therapeutic Approaches
    Hellenic J Cardiol 2011; 52: 30-40 Review Article The Role of Inflammation in Heart Failure: New Therapeutic Approaches 1 1 1,2 1 EVANGELOS OIKONOMOU , DIMITRIS TOUSOULIS , GERASIMOS SIASOS , MARINA ZAROMITIDOU , 2 1 ATHANASIOS G. PAPAVASSILIOU , CHRISTODOULOS STEFANADIS 1First Department of Cardiology, University of Athens Medical School, ‘Hippokration’ Hospital, 2Department of Biological Chemistry, University of Athens Medical School, Athens, Greece Key words: eart failure (HF) is a syndrome part due to an imbalance between increas- Inflammation, that has shown increasing mor- es in inflammatory and anti-inflammatory heart failure, bidity and mortality during the mediators. Table 1 gives a summary of the proinflammatory H cytokines. last decades. Apart from myocardial hy- many cytokines that are implicated in the pertrophy, the pathogenetic mechanisms pathogenesis of HF. of HF also include deregulation of the neurohormonal system, with disturbance Tumour necrosis factor alpha (TNF-α) of the balance between sympathetic and parasympathetic tone, and disruption of This factor, which is also produced in my- the renin-angiotensin-aldosterone sys- ocardial cells, took its name from the ini- tem.1-5 The important role of inflamma- tial observation that it exerts an inhibi- tion in HF has also been recognised.6 The tory effect on various tumour cells.31,32 It inflammatory process can cause myocar- seems that both TNF-α and other related Manuscript received: dial damage, while inflammatory agents molecules cause apoptosis of myocardial October 21, 2009; Accepted: contribute to the worsening and progres- cells via mechanisms of cell death (Table 6,7 33 February 10, 2010. sion of HF. In this article we will review 2).
    [Show full text]
  • Cardiac Stem Cells: a Promising Treatment Option for Heart Failure (Review)
    EXPERIMENTAL AND THERAPEUTIC MEDICINE 5: 379-383, 2013 Cardiac stem cells: A promising treatment option for heart failure (Review) XIAOHUI ZHAO and LAN HUANG Department of Cardiology, Xinqiao Hospital, Third Military Medical University, Chongqing 400037, P.R. China Received August 29, 2012; Accepted October 18, 2012 DOI: 10.3892/etm.2012.854 Abstract. Cardiovascular diseases are the most common 1. Introduction cause of death in the world. The development of heart failure is mainly due to the loss of cardiomyocytes following myocardial It was previously considered that the regeneration of the heart infarction and the absence of endogenous myocardial repair. was impossible to affect on a cellular level and that the heart Numerous studies have focused on cardiac stem cells (CSCs) was a terminally differentiated organ with no potential for due to their therapeutic benefit, particularly in the treatment of regeneration. The general opinion was that cardiomyocytes heart failure. It has previously been demonstrated that CSCs are rapidly proliferate during the embryonic and fetal period but able to promote the regeneration of cardiomyocytes in animals exit the cell cycle soon after birth (1-3). However, cardiac following myocardial infarction. However, the underlying stem cells (CSCs) have been successfully identified in the mechanism(s) remain unclear. This review mainly discusses hearts of rats, mice, dogs and humans (4-9). Thus, the heart's the cardioprotective effect of CSCs and the effect of CSCs on own regenerative potential opens up a new paradigm in the function of cardiomyocytes, and compares the efficacies cardiology. of CSCs from rats, mice and humans, thereby contributing to A number of studies have demonstrated that the application an improved understanding of CSCs as a promising treatment of stem cells by injection into the cardiac muscle or coronary option for heart failure.
    [Show full text]
  • Essential Role of STAT3 for Embryonic Stem Cell Pluripotency (Leukemia Inhibitory Factor͞cytokine Signaling͞jak-STAT Pathway͞embryonic Stem Cell Differentiation)
    Proc. Natl. Acad. Sci. USA Vol. 96, pp. 2846–2851, March 1999 Cell Biology Essential role of STAT3 for embryonic stem cell pluripotency (leukemia inhibitory factorycytokine signalingyJAK-STAT pathwayyembryonic stem cell differentiation) REGINA RAZ*, CHIEN-KUO LEE*, LINDA A. CANNIZZARO†,PETER D’EUSTACHIO‡, AND DAVID E. LEVY*§ Departments of *Pathology and ‡Biochemistry and Kaplan Comprehensive Cancer Center, New York University School of Medicine, New York, NY 10016; and †Department of Pathology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY 10467 Edited by James E. Darnell Jr., The Rockefeller University, New York, NY, and approved January 8, 1999 (received for review September 28, 1998) ABSTRACT Propagation of mouse embryonic stem (ES) mediator of gp130 signals (12–15), being involved in induction cells in vitro requires exogenous leukemia inhibitory factor of acute-phase response genes in hepatic cells (16), transcrip- (LIF) or related cytokines. Potential downstream effectors of tional activation and self-renewal in ES cells (17, 18), LIF- and the LIF signal in ES cells include kinases of the Src, Jak, and IL-6-dependent differentiation of M1 cells (19–21), as well as mitogen-activated protein families and the signal transducer a variety of responses in vivo (22–24). and transcriptional activator STAT3. Activation of nuclear Recently, it has become clear that STAT3 plays an impor- STAT3 and the ability of ES cells to grow as undifferentiated tant role in embryonic cell growth. Targeted disruption of the clones were monitored during LIF withdrawal. A correlation Stat3 gene in mice resulted in early embryonic lethality (25). was found between levels of STAT3 activity and maintenance In addition, ectopic overexpression of dominant-negative ver- of an undifferentiated phenotype at clonal density.
    [Show full text]
  • C-Src and IL-6 Inhibit Osteoblast Differentiation and Integrate IGFBP5 Signalling
    ARTICLE Received 2 Aug 2011 | Accepted 16 Dec 2011 | Published 17 Jan 2012 DOI: 10.1038/ncomms1651 c-Src and IL-6 inhibit osteoblast differentiation and integrate IGFBP5 signalling Barbara Peruzzi1,2, Alfredo Cappariello2, Andrea Del Fattore1,2, Nadia Rucci1, Fabrizio De Benedetti2 & Anna Teti1 Interleukin-6 (IL-6) and c-Src impair osteoblast maturation in vitro and in vivo. Given the similar effects of these factors, they are likely to establish a functional loop to maintain osteoblasts in a less mature status. Here we describe a pathway whereby c-Src stimulates IL-6 expression through the STAT3 factor, which, in response to IL-6 induces insulin-like growth factor 5 (IGFBP5), a c-Src activating factor that amplifies this loop only in immature osteoblasts. In contrast, in mature osteoblasts, IGFBP5 is enhanced by Runx2, but is no longer able to stimulate c-Src activation, as this tyrosine kinase at this stage is downregulated. We find that the IGFBP5 produced by osteoblasts stimulates osteoclastogenesis and bone resorption, acting as an osteoblast–osteoclast coupling factor. Finally, we demonstrate that the integrated actions of c-Src, IL-6 and IGFBP5 also have a role in vivo. We conclude that this pathway is relevant for bone metabolism, both in physiological and in pathological conditions. 1 Department of Experimental Medicine, University of L’Aquila, Via Vetoio – Coppito 2, L’Aquila 67100, Italy. 2 Ospedale Pediatrico Bambino Gesù, Rome 00165, Italy. Correspondence and requests for materials should be addressed to A.T. (email: [email protected]). NatURE COMMUNicatiONS | 3:630 | DOI: 10.1038/ncomms1651 | www.nature.com/naturecommunications © 2012 Macmillan Publishers Limited.
    [Show full text]
  • Sandwich Elisas Unique Targets for Innovative Research
    Sandwich ELISAs Unique targets for innovative research 2400 TARGETS 15 SPECIES 1 MANUFACTURER Over 2,400 kits available Pre-coated 96-well strip plates Validated on serum, plasma and media Manufactured in the U.S.A. Over 2,000 publications Risk-free guarantee SPECIES COVERED: Human, mouse, rat, pig, cow, dog, cat, horse, rhesus macaque, rabbit, chicken, dolphin, zebrafish, sigmodon, and sheep 1.888.494.8555 / RAYBIOTECH.COM RayBiotech R Empowering your proteomics SpeedE LISA Need quantitative detection in less time? The RayBio® SpeedELISA is a sandwich ELISA featuring a compressed workflow that allows full processing in only 3 hours. Over 160 kits currently available including human, mouse, and rat targets. Learn more and browse here: www.raybiotech.com/speedelisa-kits 1 1 2 2 3 ADD ANTIBODIES AND CAPTURE ABS BIND TO PLATE; WASH AND SAMPLES TO MICROPLATE ABANTIGEN COMPLEXES FORM DEVELOP COLOR custom ELISA RayBiotech has a vast library of array-validated antibody pairs you can take advantage of, even if they aren’t currently developed on the 96-well platform. Any antibody pair can be developed into a finished ELISA kit by placing an order for a “custom ELISA.” After a 5-7 week development phase, the final kit will have passed our ELISA quality control tests and be added to our stock kit inventory. The development phase only needs to occur once. If the ELISA fails development, the customer will not be charged anything. Need a custom kit for a target we don’t have a pair to? Need 384-well format? Chemiluminescence-based detection? We can do it! Immunoassay development is RayBiotech’s specialty.
    [Show full text]
  • Review on Inflammation Markers in Chronic Kidney Disease
    biomedicines Review Review on Inflammation Markers in Chronic Kidney Disease Tadej Petreski 1,2 , Nejc Piko 1,3 , Robert Ekart 2,3, Radovan Hojs 1,2 and Sebastjan Bevc 1,2,* 1 Department of Nephrology, Clinic for Internal Medicine, University Medical Centre Maribor, Ljubljanska Ulica 5, 2000 Maribor, Slovenia; [email protected] (T.P.); [email protected] (N.P.); [email protected] (R.H.) 2 Department of Internal Medicine and Department of Pharmacology, Faculty of Medicine, University of Maribor, Taborska Ulica 8, 2000 Maribor, Slovenia 3 Department of Dialysis, Clinic for Internal Medicine, University Medical Centre Maribor, Ljubljanska Ulica 5, 2000 Maribor, Slovenia; [email protected] * Correspondence: [email protected]; Tel.: +386-2-321-2845 Abstract: Chronic kidney disease (CKD) is one of the major health problems of the modern age. It represents an important public health challenge with an ever-lasting rising prevalence, which reached almost 700 million by the year 2017. Therefore, it is very important to identify patients at risk for CKD development and discover risk factors that cause the progression of the disease. Several studies have tackled this conundrum in recent years, novel markers have been identified, and new insights into the pathogenesis of CKD have been gained. This review summarizes the evidence on markers of inflammation and their role in the development and progression of CKD. It will focus primarily on cytokines, chemokines, and cell adhesion molecules. Nevertheless, further large, multicenter studies are needed to establish the role of these markers and confirm possible treatment options in everyday clinical practice.
    [Show full text]